New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
View original at globenewswire.comNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 Advancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
T1D affects approximately nine million people worldwide, and while islet cell transplantation has demonstrated potential to restore insulin independence in approximately 70% of patients receiving cadaveric islet transplantation at one year, the current approach requires chronic systemic immunosuppression.
60% confidenceCNTY-813 has the potential to deliver what no prior therapy has achieved: a functional cure for T1D without the need for chronic immunosuppression.
60% confidenceNo tumorigenesis was observed in more than 140 mice with more than three months of follow-up across one billion cells infused.
60% confidenceCNTY-813 cells containing Allo-Evasion 5.0 edits provided significant protection from NK cell clearance, induced rapid IgG cleavage of a surrogate anti-drug antibody, and demonstrated protection from antibody-mediated phagocytosis, confirming functional activity across all three engineered immune protection layers.
60% confidenceCNTY-813 has demonstrated critical prerequisites for a potentially curative islet replacement therapy: glucose-responsive function comparable to primary islets, graft stability with no evidence of tumorigenesis, and immune evasion engineered to eliminate the need for chronic immunosuppression.
60% confidenceCNTY-813 iPSC-derived islet cells rapidly restored normoglycemia in streptozotocin-rendered diabetic mice and maintained glucose control for greater than eight months following transplantation.
60% confidenceAllo-Evasion 5.0-edited cells showed comparable glucose control to non-edited cells, confirming immune evasion engineering modifications do not affect the islets' ability to control glucose.
60% confidenceCNTY-813 beta cells comprise greater than 50% of total cell composition, and greater than 98% of cells are in G1 phase, indicating cell cycle exit on par with primary islets.
60% confidenceMice transplanted with CNTY-813 maintained normal C-peptide secretion function through 42 days post-transplant under allogeneic immune pressure, while unedited islet grafts showed rapid functional deterioration and allo-rejection.
60% confidenceCentury Therapeutics is confident in its readiness for clinical trials and the potential to scale for broad patient access, with IND submission on track for Q4 2026 and initial clinical data anticipated in 2H 2027.
60% confidence